drugset

drugset / Trial / NCT06238466

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

NCT06238466 ↗

Phase 1 Active not recruiting 98 enrolled AstraZeneca Parexel · collab

RandomizedSequentialDouble-blindTreatment

Summary

A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia.

Timeline

Start: 2024-01-16
Primary completion: 2025-12-01
Completion: 2026-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	AZD1705	Unknown	—	Subcutaneous

Indications